Abstract：Since December 2019, a new type of coronavirus pneumonia (coronavirus disease 2019,COVID-19) has been emerging and has attracted widespread attention. Because of its characteristics of rapid spread, wide spread, long incubation period and high infection rate, a few pregnant women are infected. In order to better cooperate with the clinical pharmaceutical care, the pregnancy pharmaceutical care points of antiviral drugs mentioned in COVID-19 diagnosis and treatment guidelines are specially sorted out. It aims to provide clinicians and pharmacists with a quick understanding of the characteristics, usage and dosage and precautions of recommended antiviral drugs at present, so as to ensure the safety and rational use of drugs and improve the treatment effect of patients with new crown pneumonia.
李轶凡, 袁偲偲, 周博雅, 盖迪, 王月, 冯欣. 妊娠期合并新型冠状病毒肺炎药物合理使用与药学监护[J]. 中国药学杂志, 2020, 55(10): 767-772.
LI Yi-fan, YUAN Si-si, ZHOU Bo-ya, GAI Di, WANG Yue, FENG Xin. Rational Use and Pharmaceutical Care of Coronavirus Disease 2019 during Pregnancy. Chinese Pharmaceutical Journal, 2020, 55(10): 767-772.
HUANG C, WANG Y, LI X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, pii:S0140-6736(20)30183-5.DOI:10.1016/S0140-6736(20)30183-5.
[2]
COHEN J. Chinese researchers reveal draft genome of virus implicated in Wuhan pneumonia outbreak. Washington, DC:American Association for the Advancement of Science [EB/OL]. (2020-01-11)[2020-01-21].https://www.sciencemag.org/news/2020/01/chinese-researchers-reveal-draft-genomevirus-implicated-wuhan-pneumonia-outbreak.
[3]
WORLD HEALTH ORGANIZATION. Novelcoronavirus-China[EB/OL].(2020-01-12)[2020-01-19].http://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/.
[4]
ZHAO Y, ZOU L, WANG L, et al. Management strategy of SARA-CoV-2 infection in pregnancy [J]. Chin J Obstet Gynecol(中华妇产科杂志),2020,55(2):75-76.
[5]
WANG X Y, WU J, LU X H, et al. Recommendations for management strategies of pregnant women with new coronavirus (2019-nCoV) infection in Henan Province [J/OL]. J Zhengzhou Univ, Med Sci(郑州大学学报,医学版),2020. DOI:10.13705/j.issn.1671-6825.2020.01.167
[6]
MATERNAL AND FETAL EXPERTS COMMITTEE, CHINESE PHYSICIAN SOCIETY OF OBSTETRICS AND GYNECOLOGY, CHINESE MEDICAL DOCTOR ASSOCIATION,et al. Proposed management of COVID-19 during pregnancy and puerperium[J]. Chin J Perinat Med, 2020, 23 (2): 73-79.
[7]
NATIONAL HEALTH COMMISSION OF THE PEOPLE'S REPUBLIC OF CHINA. Guidelines for diagnosis and treatment of coronavirus disease 2019 trail version 6 [EB/OL]. National Health Commission of the People's Republic of China, 2020. (2020-03-07) [2020-04-28]. http://www.nhc.gov.cn/jkj/s3577/202003/4856d5b0458141fa9f376853224d41d7/files/4132bf035bc242478a6eaf157eb0d979.pdf.
[8]
LIU J X, CHEN W M. Adverse reactions of interferon in clinical application[J]. Public Med Forum Mag(基层医学论坛), 2010, 14(22):745-746.
[9]
YANG H, ZHOU G Q, HE F C. The mechanism, efficacy and influencing factor of interferon-α therapy in chronic hepatitis B[J]. Inter J Epidemiol Infect Dis(国际流行病学传染病学杂志),2006, 33(4):247-250.
[10]
HUANG Z H, YU G Z. Comparative study of curative effect between interferon and ganciclovir in the treatment of infants with respiratory syncytial virus pneumonia[J]. J Clin Pulm Med(临床肺科杂志), 2014,19(1):46-48.
[11]
DONG A Q, XU Y. Research progress of pulmonary inhalation delivery System [J]. Jiangxi Med J(江西医药), 2007, 42(1):82-85.
[12]
MA J G,ZHA L. Short-term effect and long-term prognosis evaluation of interferon a1b in treatment of children with bronchiolitis[J]. J Clin Pulm Med(临床肺科杂志), 2019,24(10):1842-1846.
[13]
LI Y R, XIE W. Adverse reactions and treatment of interferon alpha-part of the interpretation of chronic hepatitis B prevention and treatment guidelines[J]. Chin J Med(中国医刊), 2007,42(11):5-7.
[14]
WU L,XIE W. Adverse reactions of interferon-α and its countermeasures[J]. Chin Clin Dr(中国临床医生杂志), 2012,40(4):18-20.
[15]
LI M H, XIE Y. Expert consensus on clinical management of adverse reactions in interferon-αtherapy for chronic viral hepatitis[J]. Chin J Exp Clin Infect Dis, Electron Ed(中华实验和临床感染病杂志,电子版), 2014,30(11):1106-1111.
[16]
ZHANG M M, ZHANG H, LI Y, et al. Clinical observation of myelosuppression induced by interferon combined with ribavirin in the treatment of chronic hepatitis C and its symptomatic treatment[J]. Pharm Care Res(药学服务与研究), 2017,17(1):43-45.
[17]
WILLIAM G P, SUSANNA N, ARTHUR Y K, et al. IDSA/AASLD response to cochrane review on direct-acting antivirals for hepatitis C[J]. Clin Infect Dis, 2017, 65(11):1773-1775.
[18]
REGIERER A C, SCHULZ C O, KUEHNHARDT D, et al. Interferon-α therapy for chronic myeloid leukemia during pregnancy[J]. Am J Hematol, 2006, 81(2):149-150.
[19]
YOSHIDA Y, KATSURADA T, NAKABOU Y, et al. Efficacy of interferon-alpha in essential thrombocythemia during pregnancy[J]. An Hematol, 2017, 96(5):877-878.
[20]
BROJENI P Y, MATOK I, BOURNISSEN F G, et al. A systematic review of the fetal safety of interferon alpha[J]. Reprod Toxicol, 2012, 33(3):265-268.
[21]
FRITZ M, VATS K, GOYAL R K. Neonatal lupus and lUGR following alpha-interferon therapy during pregnancy[J]. J Perinatol,2005, 25(8):552-554
[22]
SUN D L,ZHENG C H. Safety of anti-hepatitis B virus therapy during pregnancy and lactation [J]. Chin J Mod Appl Pharm(中国现代应用药学), 2017,34(11):1635-1642.
[23]
PONS J C, LEBON P, FRYDMAN R, et al. Pharmacokinetics of interferon-alpha in pregnantwomen and fetoplacental passage[J]. Fetal Diagn Ther, 1995,10(1):7-10.
[24]
FDALABEL. Interferon alfa-2a, recombinant injection[EB/OL]. US FDA,2006.(2006-08-29) [2020-04-12]. https://www.fda.gov/drugs/drug safety and availability.
JIANG X X. Study on synthesis of new HIV protease inhibitors[D]. Shanghai:Tongji University, 2003.
[27]
ZHANG X Y, LIU Z Y, LI T S. Progress in clinical application of lopinavir / ritonavir against human immunodeficiency virus[J]. Natl Med J China(中华医学杂志), 2015,95(35):2893-2896.
[28]
KIM U J, WON E J, KEE S J, et al. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome[J]. Antivir Ther, 2016, 21(5):455-459.
[29]
MEYER B, BASRA A, ABERLE S, et al. MERS-COV disease associated adrs-a case report[J]. Crit Care Med, 2015, 43(12):308.
[30]
CHU M C, CHENG V C, HUNG I F, et al. Role of lopinavir/ritonavir in the treatment of SARS:initial virological and clinical findings[J]. Thorax, 2004, 59(3):252-256.
[31]
JIANG H, DENG H F, WANG Y,et al. The possibility of using lopinave /litonawe (LPV/r) as treatment for novel coronavirus(2019-nCov)pneumonia: a quick systematic review based on earlier coronavirus clinical studies[J]. Chin J Emerg Med(中华急诊医学杂志), 2020,29(2):182-186.
[32]
ZHANG Y L, LIU Z Y. Progress of clinical application of lopinavir / ritonavir in the treatment of HIV-1 infection[C].The 13th National Conference on Infectious Diseases of Chinese Medical Association,2014.
[33]
FDALABEL. Lopinavir and ritonavir tablet,oral solution [EB/OL]. US FDA, 2015. (2015-11-10) [2020-04-12]. https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/
[34]
PASLEY M V, MARTINEZ M, HERMES A, et al. Safety and efficacy of lopinavir/ritonavir during pregnancy: a systematic review[J]. Aids Rev, 2013, 15(1):38-48.
[35]
PERRY M E, TAYLOR G P, SABIN C A, et al. Lopinavir and atazanavir in pregnancy:comparable infant outcomes, virological efficacies and preterm delivery rates[J]. Hiv Med, 2016,17(1):28-35.
[36]
ROBERTS S S, MARTINEZ M, COVINGTON D L, et al. Lopinavir/ritonavir in pregnancy[J]. J Acquir Immune Defic Syndr, 2009,51(4):456-461.
[37]
CHRISTIANA S, ADRIANA W, FORSTER J E, et al. Maternal lopinavir/ritonavir is associated with fewer adverse events in infants than nelfinavir or atazanavir[J]. Infect Dis Obstet Gynecol, 2016, 2016:1-9.
[38]
BRITES C, NÓBREGA I, LUZ E, et al. Raltegravir versus lopinavir/ritonavir for treatment of HIV-infected late-presenting pregnant women[J]. HIV Clin Trials, 2018,19(3):94-100.
[39]
WHITLEY R J, KIMBERLIN D W. Treatment of viral infections during pregnancy and the neonatal period[J]. Clin Perinatol, 1997, 24(1):267-283.
[40]
GHAZI SULIMAN M A, OGUNGBENRO K, KOSMIDIS C, et al. The effect of veno-venous ECMO on the pharmacokinetics of ritonavir, darunavir, tenofovir and lamivudine[J]. J Crit Care,2017,40:113-118.
[41]
YAO Y M,MU J,SUN J, et al. Progress on pharmacokinetics of lopinavir[J]. J Pharm Pract(药学实践杂志),2012,30(5):20-23.
[42]
GORNY M, ROHM S, LAER S, et al. Pharmacogenomic adaptation of antiretroviral therapy:overcoming the failure of lopinavir in an African infant with CYP2D6 ultrarapid metabolism[J]. Eur J Clin Pharmacol, 2010,66(1):107-108.
[43]
SALMAN S, BAIWOG F, PAGE-SHARP M, et al. Optimal antimalarial dose regimens for chloroquine in pregnancy based on population pharmacokinetic modelling[J]. Int J Antimicrob Agents, 2017, 50(4):542-551.
[44]
KLINGER G, MORAD Y, WESTALL C A, et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases[J]. Lancet, 2001, 358(9284):813-814.
[45]
CHEN Y, FENG X,YANG H, et al. Principles and contraindications of commonly used Chinese patent medicines for diseases in pregnancy[J]. Chin J Fam Plann Gynecotokol(中国计划生育和妇产科), 2015,7(2):5-8.
[46]
WANG Q L,CHENG Y B. Statistics and analysis of the variations of Chinese patent medicines related to contraindications of pregnancy in the pharmacopoeia of the People's Republic of China in 2010[J]. Chin J Inf Tradit Chin Med(中国中医药信息杂志), 2011,18(10):100-102.
2020, Vol. 55 
